Trial of Parkinson's and Zoledronic Acid (TOPAZ)
Researchers are partnering with individuals who have Parkinson's Disease or another form of parkinsonism to evaluate how a medication can help. Join our compensated study today!
Fast Facts
parkinson's disease or other parkinsonism
60+ Years Old
Compensation Provided
Conducted across the US
Study Background
UCSF and Sutter Health researchers invite you to join the TOPAZ study.
The TOPAZ study will test if a medicine called zoledronate can prevent fractures and decrease the risk of dying in people with Parkinson’s Disease and parkinsonism.
If you have Parkinson’s Disease or another form of parkinsonism, such as progressive supranuclear palsy, multiple system atrophy, cortical basal degeneration, vascular parkinsonism, dementia with Lewy bodies, or another form of neurodegenerative parkinsonism, you may be eligible.
Your participation in this research study may help researchers improve treatment approaches for Parkinson’s and related diseases. Help advance research today and join our compensated study!
Study Background
UCSF and Sutter Health researchers invite you to join the TOPAZ study.
The TOPAZ study will test if a medicine called zoledronate can prevent fractures and decrease the risk of dying in people with Parkinson’s Disease and parkinsonism.
If you have Parkinson’s Disease or another form of parkinsonism, such as progressive supranuclear palsy, multiple system atrophy, cortical basal degeneration, vascular parkinsonism, dementia with Lewy bodies, or another form of neurodegenerative parkinsonism, you may be eligible.
Your participation in this research study may help researchers improve treatment approaches for Parkinson’s and related diseases. Help advance research today and join our compensated study!
Additional Information
The primary aim of the study is to evaluate the efficacy of a single infusion of zoledronate (ZA, 5mg) to reduce the risk of fractures in patients with Parkinson’s Disease or neurodegenerative parkinsonism.
You may qualify for this study if you meet the following criteria.
Key Criteria:
- 60 years of age or older
- Able to read & speak English
- Have Parkinson’s disease or another form of parkinsonism, including:
- progressive supranuclear palsy
- multiple system atrophy
- cortical basal degeneration
- vascular parkinsonism
- dementia with Lewy bodies
- another form of neurodegenerative parkinsonism
- Have not had a hip fracture
Patients who wish to enroll will be directed to an interactive electronic consent (eConsent) and enrollment platform. Following an initial eligibility screening questionnaire (to confirm eligibility), participants review and agree to an eConsent, followed by a baseline questionnaire.
If a participant is determined to be eligible following these steps, they may be scheduled for a Telemedicine assessment to further confirm the PD or parkinsonism diagnosis, unless they have been referred directly from a participating neurologist.
If confirmed, the participant will be mailed a supply of vitamin D3 and instructed to take one vitamin D tablet every day for 2 months.
Lastly, a Nurse Home Visit will be scheduled and conducted to confirm final eligibility, randomization, and administration of the study drug, if appropriate. This will be a one-time infusion of zoledronate. Participants who are randomized will be contacted every 4 months for at least 2 years to determine if they have had any fractures.
